Armstrong, A. J., Sartor, O., Saad, F., Czernin, J., Shore, N. D., Kendi, A. T., … Morris, M. J. (2022). 1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. In Annals of Oncology (Vol. 33, pp. S1169–S1170). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1504

Armstrong, A. J., O. Sartor, F. Saad, J. Czernin, N. D. Shore, A. T. Kendi, T. M. Beer, et al. “1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial.” In Annals of Oncology, 33:S1169–70. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1504.

Armstrong AJ, Sartor O, Saad F, Czernin J, Shore ND, Kendi AT, et al. 1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. In: Annals of Oncology. Elsevier BV; 2022. p. S1169–70.

Armstrong, A. J., et al. “1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1169–70. Crossref, doi:10.1016/j.annonc.2022.07.1504.

Armstrong AJ, Sartor O, Saad F, Czernin J, Shore ND, Kendi AT, Beer TM, Vaishampayan N, El-Haddad G, Wu J, Mirante O, Morris MJ. 1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. Annals of Oncology. Elsevier BV; 2022. p. S1169–S1170.